CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study

Abstract

Purpose This study aimed to systematically identify and annotate oropharyngeal cancer (OPC) genetic risk, construct OPC risk prediction models, and identify candidate drug targets for OPC treatment. Methods The OPC genome-wide association study was conducted in the UK Biobank involving 208 OPC patients and 328,248 healthy individuals. Functional annotations were performed using the FUMA website and the Sclinker statistical framework. OPC risk prediction models were constructed using logistic regression. Mendelian randomization (MR) was employed to identify potential OPC-related drug target genes. Results We identified 43 OPC risk genetic variants with p < 1E-06, which mapped to 7 independent loci. We also revealed significant tissue-level OPC single nucleotide polymorphism heritability enrichments in heart, kidney, and muscle, and cell-type specific enrichments in B cells, T cells, endothelial cells, epithelial cells, and fibroblasts. We further constructed four OPC risk prediction models, and the fully-adjusted model demonstrated moderate discriminative ability in internal validation. Additionally, MR analysis identified 160 nominate OPC-associated candidate druggable genes using expression/protein quantitative trait loci as instrumental variables. Drugs targeting these genes, such as Daunorubicin, Gefitinib, and Ibrutinib had been approved as anti-cancer agents. Conclusion These results advanced our understanding of the genetic architecture of OPC and provided insights into its risk prediction and potential drug targets, contributing to future development of improved OPC prevention and treatment strategies.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00405-026-10663-5

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 44 references

Research works printed but not linked: 2

  1. Garst J (2007) Topotecan: an evolving option in the treatment of relapsed small cell lung cancer. Ther Clin Risk Manag 3(6):1087–1095
  2. (2012) Aldesleukin. In: LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. https://www.ncbi.nlm.nih.gov/books/NBK547852/

Cited by

See all 1

Metadata

Authors
Li, J., Qiu, K., Rao, Y., Cheng, D., Song, Y., Shao, X., Jiang, C., Shu, T., Xu, W., Zhao, Y., & Ren, J.
Affiliations
  • Sichuan University (CN)
  • Princess Margaret Cancer Centre (CA)
Corresponding author
  • Xu, Wei
  • Zhao, Yu
  • Ren, Jianjun
Venue
European Archives of Oto-Rhino-Laryngology
Published
2026-10-04
ISSN
  • 0937-4477 (ISSN-L)
  • 1434-4726
OpenAlex
W7219746469
Cited by
0
References
44
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Archives of Oto-Rhino-Laryngology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82272777, 82471153, 82403589)
  • Science and Technology Department of Sichuan Province (2025ZNSFSC1528, 2025ZNSFSC1530)
  • Chengdu Science and Technology Bureau (2024-YF05-00908-SN)
  • 1·3·5 project for disciplines of excellence-Clinical Research Fund, West China Hospital, Sichuan University (2025HXFH010)
  • 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (2025-522)
  • Sichuan University Interdisciplinary Innovation Fund
Topics
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
oropharyngeal cancer, genetic susceptibility, risk prediction, druggable targets, UK Biobank, cancer genetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study. https://app.cochat.ai/papers/10.1007/s00405-026-10663-5
The paper
Li, J., Qiu, K., Rao, Y., Cheng, D., Song, Y., Shao, X., Jiang, C., Shu, T., Xu, W., Zhao, Y., & Ren, J. (2026). Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10663-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.